Drug Profile


Alternative Names: cA2; CenTNF; Remicade; TA-650

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centocor
  • Developer Centocor; Janssen Biotech; Merck & Co; Mitsubishi Tanabe Pharma Corporation; National Jewish Medical and Research Center; Xian-Janssen
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucocutaneous lymph node syndrome; Crohn's disease; Juvenile rheumatoid arthritis; Ankylosing spondylitis; Behcet's syndrome; Sarcoidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Mucocutaneous lymph node syndrome; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Discontinued Berylliosis; Hepatitis C; Pyoderma

Most Recent Events

  • 20 Sep 2017 Pfizer initiates litigation against Johnson and Johnson to allow competition for biologics and expand options for patients in USA
  • 18 May 2017 Mitsubishi Tanabe Pharma receives an approval for partial change in administration/dosage for Crohn's disease in Japan
  • 26 Dec 2016 Launched for Mucocutaneous Lymph Node Syndrome (In children, In infants) in Japan (IV) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top